Picture of boy being examining by doctor at a tuberculosis sanatorium

Understanding our future through Open Access research about our past...

Strathprints makes available scholarly Open Access content by researchers in the Centre for the Social History of Health & Healthcare (CSHHH), based within the School of Humanities, and considered Scotland's leading centre for the history of health and medicine.

Research at CSHHH explores the modern world since 1800 in locations as diverse as the UK, Asia, Africa, North America, and Europe. Areas of specialism include contraception and sexuality; family health and medical services; occupational health and medicine; disability; the history of psychiatry; conflict and warfare; and, drugs, pharmaceuticals and intoxicants.

Explore the Open Access research of the Centre for the Social History of Health and Healthcare. Or explore all of Strathclyde's Open Access research...

Image: Heart of England NHS Foundation Trust. Wellcome Collection - CC-BY.

Identification and hit-to-lead optimization of a novel class of CB1 antagonists

Letourneau, Jeffrey J and Jokiel, Patrick and Olson, John and Riviello, Christopher M and Ho, Koc-Kan and McAleer, Lihong and Yang, Jingchun and Swanson, Robert N and Baker, James and Cowley, Phillip and Edwards, Darren and Ward, Nick and Ohlmeyer, Michael H J and Webb, Maria L (2010) Identification and hit-to-lead optimization of a novel class of CB1 antagonists. Bioorganic and Medicinal Chemistry Letters, 20 (18). pp. 5449-5453. ISSN 0960-894X

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

The discovery, synthesis and preliminary structure-activity relationships (SARs) of a novel class of CB1 antagonists is described. Initial optimization of benzimidazole-based screening hit 4 led to the identification of 'inverted' indole-based lead compound 18c with improved properties versus compound 4 including reduced AlogP, improved microsomal stability and improved aqueous solubility. Compound 18c demonstrates in vivo CB1 antagonist efficacy (CB1 agonist induced hypothermia model) and is orally bioavailable in rat.